Do analysts rate VYNE or ALP?

Portage Biotech has a consensus price target of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Portage Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to VYNE or ALP?

In the previous week, VYNE Therapeutics had 7 more articles in the media than Portage Biotech. MarketBeat recorded 8 mentions for VYNE Therapeutics and 1 mentions for Portage Biotech. VYNE Therapeutics' average media sentiment score of 0.04 beat Portage Biotech's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, KYNB or ALP?

Kyntra Bio has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.38 $183.45M $40.46 0.17 Portage Biotech $100K 47.53 -$38.63M -$8.18 N/A

Is KYNB or ALP more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Portage Biotech's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -36.71% Portage Biotech N/A N/A N/A

Does the media favor KYNB or ALP?

In the previous week, Kyntra Bio had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Kyntra Bio and 1 mentions for Portage Biotech. Kyntra Bio's average media sentiment score of 0.93 beat Portage Biotech's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ALP or BGM?

Portage Biotech currently has a consensus price target of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Portage Biotech is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ALP or BGM?

BGM Group has higher revenue and earnings than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Portage Biotech $100K 47.53 -$38.63M -$8.18 N/A BGM Group $37.92M 0.73 -$19.94M N/A N/A

Is ALP or BGM more profitable?

Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A BGM Group N/A N/A N/A

Does the media refer more to ALP or BGM?

In the previous week, BGM Group had 3 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for BGM Group and 1 mentions for Portage Biotech. BGM Group's average media sentiment score of 0.57 beat Portage Biotech's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALP or ATNM more profitable?

Portage Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to ALP or ATNM?

In the previous week, Actinium Pharmaceuticals had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Actinium Pharmaceuticals and 1 mentions for Portage Biotech. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Portage Biotech's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PLRZ or ALP?

Portage Biotech has a consensus target price of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Portage Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, PLRZ or ALP?

Polyrizon has higher earnings, but lower revenue than Portage Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Portage Biotech $100K 47.53 -$38.63M -$8.18 N/A

Is PLRZ or ALP more profitable?

Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Portage Biotech N/A N/A N/A

Does the media prefer PLRZ or ALP?

In the previous week, Polyrizon had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for Portage Biotech. Polyrizon's average media sentiment score of 1.32 beat Portage Biotech's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Portage Biotech (ALP) Competitors

$0.20 -0.01 (-2.55%)

As of 04:00 PM Eastern

Compare

ALP vs. VYNE, KYNB, BGM, ATNM, and PLRZ

Should you buy Portage Biotech stock or one of its competitors? MarketBeat compares Portage Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Portage Biotech include VYNE Therapeutics (VYNE), Kyntra Bio (KYNB), BGM Group (BGM), Actinium Pharmaceuticals (ATNM), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry.

How does Portage Biotech compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Portage Biotech (NASDAQ:ALP) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Portage Biotech has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. Portage Biotech's return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Portage Biotech	N/A	N/A	N/A

VYNE Therapeutics has higher revenue and earnings than Portage Biotech. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
Portage Biotech	$100K	47.53	-$38.63M	-$8.18	N/A

In the previous week, VYNE Therapeutics had 7 more articles in the media than Portage Biotech. MarketBeat recorded 8 mentions for VYNE Therapeutics and 1 mentions for Portage Biotech. VYNE Therapeutics' average media sentiment score of 0.04 beat Portage Biotech's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Portage Biotech has a consensus price target of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

VYNE Therapeutics beats Portage Biotech on 8 of the 15 factors compared between the two stocks.

How does Portage Biotech compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Portage Biotech (NASDAQ:ALP) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Kyntra Bio has a net margin of 2,199.13% compared to Portage Biotech's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Portage Biotech	N/A	N/A	N/A

In the previous week, Kyntra Bio had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Kyntra Bio and 1 mentions for Portage Biotech. Kyntra Bio's average media sentiment score of 0.93 beat Portage Biotech's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.38	$183.45M	$40.46	0.17
Portage Biotech	$100K	47.53	-$38.63M	-$8.18	N/A

Kyntra Bio has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Kyntra Bio presently has a consensus price target of $32.50, suggesting a potential upside of 366.28%. Portage Biotech has a consensus price target of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's higher possible upside, analysts clearly believe Portage Biotech is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kyntra Bio beats Portage Biotech on 12 of the 15 factors compared between the two stocks.

How does Portage Biotech compare to BGM Group?

Portage Biotech (NASDAQ:ALP) and BGM Group (NASDAQ:BGM) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Portage Biotech has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

Portage Biotech currently has a consensus price target of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Portage Biotech is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has higher revenue and earnings than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	$100K	47.53	-$38.63M	-$8.18	N/A
BGM Group	$37.92M	0.73	-$19.94M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
BGM Group	N/A	N/A	N/A

13.4% of Portage Biotech shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BGM Group had 3 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for BGM Group and 1 mentions for Portage Biotech. BGM Group's average media sentiment score of 0.57 beat Portage Biotech's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BGM Group beats Portage Biotech on 6 of the 11 factors compared between the two stocks.

How does Portage Biotech compare to Actinium Pharmaceuticals?

Portage Biotech (NASDAQ:ALP) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Portage Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Portage Biotech has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	$100K	47.53	-$38.63M	-$8.18	N/A
Actinium Pharmaceuticals	$90K	302.07	-$48.82M	-$0.75	N/A

Portage Biotech has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Portage Biotech presently has a consensus price target of $2.00, indicating a potential upside of 887.65%. Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 477.03%. Given Portage Biotech's higher probable upside, equities research analysts clearly believe Portage Biotech is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Actinium Pharmaceuticals had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Actinium Pharmaceuticals and 1 mentions for Portage Biotech. Actinium Pharmaceuticals' average media sentiment score of 0.75 beat Portage Biotech's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Actinium Pharmaceuticals beats Portage Biotech on 7 of the 13 factors compared between the two stocks.

How does Portage Biotech compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Portage Biotech (NASDAQ:ALP) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Portage Biotech has a consensus target price of $2.00, suggesting a potential upside of 887.65%. Given Portage Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.4% of Portage Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Portage Biotech	N/A	N/A	N/A

Polyrizon has a beta of -1.59, meaning that its stock price is 259% less volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Polyrizon has higher earnings, but lower revenue than Portage Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Portage Biotech	$100K	47.53	-$38.63M	-$8.18	N/A

In the previous week, Polyrizon had 1 more articles in the media than Portage Biotech. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for Portage Biotech. Polyrizon's average media sentiment score of 1.32 beat Portage Biotech's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Portage Biotech beats Polyrizon on 6 of the 9 factors compared between the two stocks.

Get Portage Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALP vs. The Competition

Export

Metric	Portage Biotech	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$4.88M	$946.10M	$6.61B	$12.18B
Dividend Yield	N/A	4.84%	31.69%	8.55%
P/E Ratio	N/A	0.99	19.20	21.46
Price / Sales	47.53	107.81	129.20	88.45
Price / Cash	N/A	20.06	165.24	59.05
Price / Book	0.72	8.45	12.86	6.06
Net Income	-$38.63M	-$3.57M	$120.03M	$336.44M
7 Day Performance	-39.01%	-0.36%	-2.39%	-2.14%
1 Month Performance	-39.01%	-6.22%	-4.31%	-3.32%
1 Year Performance	N/A	26.14%	10.07%	13.49%

Portage Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALP Portage Biotech	1.205 of 5 stars	$0.20 -2.6%	$2.00 +887.7%	N/A	$4.88M	$100K	N/A	6
VYNE VYNE Therapeutics	0.757 of 5 stars	$0.90 +0.5%	N/A	-60.9%	$29.80M	$570K	N/A	30	News Coverage Short Interest Increase Gap Down
KYNB Kyntra Bio	4.0312 of 5 stars	$7.22 -1.2%	$32.50 +350.5%	N/A	$29.55M	$6.44M	0.18	570	News Coverage
BGM BGM Group	0.4407 of 5 stars	$0.28 -6.3%	N/A	-97.3%	$29.17M	$37.92M	N/A	298	Earnings Report Short Interest Increase
ATNM Actinium Pharmaceuticals	2.5972 of 5 stars	$0.90 flat	$5.00 +455.6%	-52.3%	$28.24M	$90K	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALP) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Portage Biotech (ALP) Competitors

ALP vs. VYNE, KYNB, BGM, ATNM, and PLRZ

How does Portage Biotech compare to VYNE Therapeutics?

Summary

How does Portage Biotech compare to Kyntra Bio?

Summary

How does Portage Biotech compare to BGM Group?

Summary

How does Portage Biotech compare to Actinium Pharmaceuticals?

Summary

How does Portage Biotech compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALP vs. The Competition

Portage Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Portage Biotech (ALP) Competitors

ALP vs. VYNE, KYNB, BGM, ATNM, and PLRZ

How does Portage Biotech compare to VYNE Therapeutics?

Is VYNE or ALP more profitable?

Which has higher valuation and earnings, VYNE or ALP?

Does the media refer more to VYNE or ALP?

Do insiders & institutionals hold more shares of VYNE or ALP?

Which has more volatility and risk, VYNE or ALP?

Do analysts rate VYNE or ALP?

Summary

How does Portage Biotech compare to Kyntra Bio?

Is KYNB or ALP more profitable?

Does the media favor KYNB or ALP?

Do institutionals and insiders hold more shares of KYNB or ALP?

Which has preferable valuation & earnings, KYNB or ALP?

Which has more volatility & risk, KYNB or ALP?

Do analysts prefer KYNB or ALP?

Summary

How does Portage Biotech compare to BGM Group?

Which has more volatility & risk, ALP or BGM?

Do analysts recommend ALP or BGM?

Which has higher valuation & earnings, ALP or BGM?

Is ALP or BGM more profitable?

Do insiders & institutionals hold more shares of ALP or BGM?

Does the media refer more to ALP or BGM?

Summary

How does Portage Biotech compare to Actinium Pharmaceuticals?

Is ALP or ATNM more profitable?

Which has stronger valuation & earnings, ALP or ATNM?

Which has more volatility and risk, ALP or ATNM?

Do insiders and institutionals have more ownership in ALP or ATNM?

Do analysts recommend ALP or ATNM?

Does the media refer more to ALP or ATNM?

Summary

How does Portage Biotech compare to Polyrizon?

Do analysts rate PLRZ or ALP?

Do institutionals & insiders believe in PLRZ or ALP?

Is PLRZ or ALP more profitable?

Which has more volatility and risk, PLRZ or ALP?

Which has stronger earnings and valuation, PLRZ or ALP?

Does the media prefer PLRZ or ALP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALP vs. The Competition

Portage Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools